QQ客服 官方微博 反馈留言

	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial
	Yi-Long Wu; Shun Lu; Ying Cheng; Caicun Zhou; Jie Wang; Tony Mok; Li Zhang; Hai-Yan Tu; Lin Wu; Jifeng Feng
刊名	Journal of Thoracic Oncology
	2019
关键词	Chinese population nivolumab non-small cell lung cancer phase III clinical study
ISSN号	1556-0864
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/1818025
专题	四川大学
作者单位	1.Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China r Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China h Department II of Thoracic Medicine, Hunan Cancer Hospital, Changsha, China g Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China p Department of Statistics, Bristol-Myers Squibb, Lawrence Township, New Jersey, USA q Department of Immuno-oncology, Bristol-Myers Squibb, Lawrence Township, New Jersey, USA i Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China n Department of Thoracic Oncology, West China Hospital, Chengdu, China o Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China l Department of Respiratory Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China m Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China j Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China k Department of Oncology No 2.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China 3., Leningrad Regional Clinical Hospital, St. Petersburg, Russia 4.b Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China a Department of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 5.Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China f Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China
推荐引用方式 GB/T 7714	Yi-Long Wu,Shun Lu,Ying Cheng,et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial[J]. Journal of Thoracic Oncology,2019.
APA	Yi-Long Wu.,Shun Lu.,Ying Cheng.,Caicun Zhou.,Jie Wang.,...&Jianhua Chang.(2019).Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial.Journal of Thoracic Oncology.
MLA	Yi-Long Wu,et al."Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial".Journal of Thoracic Oncology (2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。